HPV vaccine may stop precancerous lesions from returning

NCT ID NCT07431502

Not yet recruiting Prevention Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether the HPV vaccine can prevent the return of high-grade squamous intraepithelial lesions (HSIL) in people who have already been treated for them. About 984 adults aged 18–55 with HPV-related HSIL of the cervix, vulva, vagina, penis, or anus will receive either the vaccine or a placebo. The goal is to see if vaccination reduces the chance of a new HSIL at the same site.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAL HIGH GRADE SQUAMOUS INTRAEPITHELIAL LESION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anal canal carcinoma in situ cervical squamous intraepithelial neoplasia penis carcinoma in situ squamous carcinoma in situ squamous cell intraepithelial neoplasia Squamous Intraepithelial Lesions vulvar intraepithelial neoplasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PATIENTS WITH PRIMARY HPV HIGH-GRADE SQUAMOUS INTRA-EPITHELIAL LESIONS (HSIL) AT ANAL SITE PATIENTS WITH PRIMARY HPV HIGH-GRADE SQUAMOUS INTRA-EPITHELIAL LESIONS (HSIL) AT CERVICAL SITE PATIENTS WITH PRIMARY HPV HIGH-GRADE SQUAMOUS INTRA-EPITHELIAL LESIONS (HSIL) AT PENILE SITE PATIENTS WITH PRIMARY HPV HIGH-GRADE SQUAMOUS INTRA-EPITHELIAL LESIONS (HSIL) AT VAGINAL SITE PATIENTS WITH PRIMARY HPV HIGH-GRADE SQUAMOUS INTRA-EPITHELIAL LESIONS (HSIL) AT VULVAR SITE

More trials for these conditions

Other studies related to the condition(s) this trial covers.